Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

• Post published:January 17, 2023
• Post category:Press Release

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

• Post published:January 15, 2023
• Post category:Press Release

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

• Post published:January 3, 2023
• Post category:Press Release

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

• Post published:December 5, 2022
• Post category:Press Release

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

• Post published:October 24, 2022
• Post category:Press Release

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

• Post published:October 15, 2022
• Post category:Press Release

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

• Post published:September 21, 2022
• Post category:Press Release

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

• Post published:September 19, 2022
• Post category:Press Release

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

• Post published:September 13, 2022
• Post category:Press Release

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

• Post published:September 9, 2022
• Post category:Press Release